OnCo
drugsProductNot mapped hereapproved

Cladribine

A one-week infusion that puts most people with hairy cell leukaemia into remission for years; also used in multiple sclerosis in tablet form.

Piro et al. (NEJM 1990) reported durable complete remissions in hairy cell leukaemia from a single 7-day course; approved 1993. Also used in mastocytosis, Langerhans cell histiocytosis, Waldenström and AML regimens (CLAG-M). Prolonged CD4 lymphopenia and infection risk; adding rituximab increases MRD-negative remission.

Loading structure…
|
Cladribine
PubChem
Modality
Purine nucleoside analogue
Mechanism
2-chlorodeoxyadenosine resists adenosine deaminase, accumulates as triphosphate in lymphocytes with high deoxycytidine kinase, and induces apoptosis in dividing and resting cells.
Brand / code
Leustatin / Litak
Medicare
Part B (clinician-administered)

Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. Generic; IV or subcutaneous for hairy cell leukaemia. (Oral cladribine, Mavenclad, is a multiple sclerosis drug and Part D.)

Commercial insurance
covered on label

Multi-source generic; covered under the medical benefit without prior authorisation in most plans, as part of standard regimens.

Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.

Not appraisedSearch NICE
Notes
Generic; standard first-line for hairy cell leukaemia. Funded routinely.
NHS England
Routinely funded for the appraised indication (or via managed access)

Sources: NICE search: cladribine. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.

Regulatory

2top

Approvals

RegionYearIndication
US1993Active hairy cell leukaemia
EU2004Hairy cell leukaemia (Litak, subcutaneous)

Trials

top
ClinicalTrials.gov · phase 2/3
refreshed 2026-09-09
110 studies23 recruiting79 Phase 230 Phase 3
Search “Cladribine” on ClinicalTrials.gov →
Counts are from a name search and may include unrelated studies; up to 100 studies are summarised.

Recruiting now (live from ClinicalTrials.gov)

Recruiting trials near you · live from ClinicalTrials.gov
Cladribine
intervention: Cladribine
Open on ClinicalTrials.gov →

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this drug: (TITLE:"Cladribine" OR ABSTRACT:"Cladribine" OR TITLE:"Leustatin" OR ABSTRACT:"Leustatin" OR TITLE:"Litak" OR ABSTRACT:"Litak") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Cladribine, not a curated reading list.

Connected

3top

Pages like this

not linked directly; found by shared links